Evidence suggested that unlike anti-immune checkpoint therapy, which simply obstructs PD-1/PD-L1 interactions, EGCG suppressed JAK/STAT signaling and downstream PD-L1 expression in melanoma cells, thereby reactivating CTLs to inhibit tumor cell growth (29). Here, SOAT1 is linked to melanoma.